Non-steroidal anti-inflammatory drugs (NSAIDs) are used for the management of various conditions, such as pain,fever, inflammation, cancer, or cardiovascular diseases. These drugs may induce injury throughout the gastrointestinaltract. NSAIDs are associated with diverse upper gastrointestinal advers...
Non-steroidal anti-inflammatory drugs (NSAIDs) are used for the management of various conditions, such as pain,fever, inflammation, cancer, or cardiovascular diseases. These drugs may induce injury throughout the gastrointestinaltract. NSAIDs are associated with diverse upper gastrointestinal adverse effects, including dyspepsia, erosions,peptic ulcer diseases and complications such as bleeding perforation. Established risk factors for these adverseeffects include age, prior ulcer, types, doses and duration of NSAIDs, concurrent other NSAIDs administration,and the concomitant uses of corticosteroids or anticoagulants. Misoprostol, proton pump inhibitors, andcyclooxygenase-2 selective inhibitors have been used to reduce the risk of NSAID-associated upper gastrointestinalevents. NSAID-induced enteropathy is more common than complications of the stomach and duodenum and isusually manifested by occult blood loss or hypoalbuminemia. Furthermore, NSAIDs induce small intestinal injuriescausing gut barrier damage, and bacterial translocation that have been proposed to be associated with the burdenof illness in decompensated chronic heart failure. However, the risk factors for NSAID-induced enteropathy andbacterial translocation, as well as its preventive measures, are not well documented.
Non-steroidal anti-inflammatory drugs (NSAIDs) are used for the management of various conditions, such as pain,fever, inflammation, cancer, or cardiovascular diseases. These drugs may induce injury throughout the gastrointestinaltract. NSAIDs are associated with diverse upper gastrointestinal adverse effects, including dyspepsia, erosions,peptic ulcer diseases and complications such as bleeding perforation. Established risk factors for these adverseeffects include age, prior ulcer, types, doses and duration of NSAIDs, concurrent other NSAIDs administration,and the concomitant uses of corticosteroids or anticoagulants. Misoprostol, proton pump inhibitors, andcyclooxygenase-2 selective inhibitors have been used to reduce the risk of NSAID-associated upper gastrointestinalevents. NSAID-induced enteropathy is more common than complications of the stomach and duodenum and isusually manifested by occult blood loss or hypoalbuminemia. Furthermore, NSAIDs induce small intestinal injuriescausing gut barrier damage, and bacterial translocation that have been proposed to be associated with the burdenof illness in decompensated chronic heart failure. However, the risk factors for NSAID-induced enteropathy andbacterial translocation, as well as its preventive measures, are not well documented.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.